Abstract
Human β-tryptase is a mast cell-specific serine protease with trypsin-like activity that is regarded to play a key role in mast cell-related disorders such as asthma. Thus, to block these disease-associated processes mediated by this protease, in the last decade a diversity of β-tryptase inhibitors has been developed, some of which are promising lead compounds for clinical development.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
Metcalfe DD, Baram D, Mekori YA (1997) Mast Cells. Physiol Rev 77:1033–1079
Payne V, Kam PCA (2004) Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia 59:695–703
Sommerhoff CP, Bode W, Pereira PJB et al. (1999) The structure of the human βII-tryptase tetramer: Fo(u)r better or worse. Proc Natl Acad Sci USA 96:10984–10991
Schechter I, Berger A (1967) On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27:157–162
Harris JL, Niles A, Burdick K et al. (2001) Definition of the extended substrate specificity determinants for β-tryptases I and II. J Biol Chem 276:34941–34947
Sommerhoff CP, Schaschke N (2007) Mast cell tryptase β as target in allergic inflammation: an evolving story. Curr Pharm Design 13:313–332
Schaschke N, Gabrijelcic-Geiger D, Dominik A et al. (2005) Affinity chromatography of tryptases: design, synthesis and characterization of a novel matrix-bound bivalent inhibitor. ChemBioChem 6:95–103
Lee AY, Hagihara M, Karmacharya R et al. (1993) Atomic structure of the trypsin-cyclotheonamide A complex: lessons for the design of serine protease inhibitors. J Am Chem Soc 115:12619–12620
Murakami Y, Takei M, Shindo K et al. (2002) Cyclotheonamide E4 and E5, new potent tryptase inhibitors from an Ircinia species of sponge. J Nat Prod 65:259–261
Schaschke N, Sommerhoff CP (2010) Upgrading a natural product: inhibition of human β-tryptase by cyclotheonamide analogues. ChemMedChem 5:367–370
Schaschke N, Dominik A, Matschiner G et al. (2002) Bivalent inhibition of β-tryptase: distance scan of neighboring subunits by dibasic inhibitors. Bioorg Med Chem Lett 12:985–988
Janke D, Sommerhoff CP, Schaschke N (2011) The arginine mimicking β-amino acid β 3hPhe(3-H2N-CH2)-OH as S1 ligand in cyclotheonamide-based β-tryptase inhibitors. Bioorg Med Chem 19:7236–7243
Krishna MT, Chauhan A, Little L et al. (2001) Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergeninduced late-phase airway obstruction in asthma. J Allergy Clin Immunol 107:1039–1045
Author information
Authors and Affiliations
Corresponding authors
Additional information
Norbert Schaschke 1989–1994 Chemiestudium an der LMU München. 1995–1998 Doktorarbeit am Max-Planck-Institut (MPI) für Biochemie, Martinsried. 1998 Promotion an der TU München. 1998–1999 Postdoc am MPI für Biochemie, dort 2000–2005 wissenschaftlicher Mitarbeiter, externe Habilitation im Fach Organische Chemie an der Universität Bielefeld. Seit 2006 Privatdozent an der Universität Bielefeld. 2007–2011 Heisenberg-Stipendiat der DFG.
Christian P. Sommerhoff 1975–1982 Medizinstudium an der Universität Bonn. 1982–1985 internistische Weiterbildung, Universität Münster. 1985–1989 wissenschaftlicher Mitarbeiter am Cardiovascular Research Institute, University of California, San Francisco. 1989–1998 wissenschaftlicher Assistent in der Abteilung für Klinische Chemie und Klinische Biochemie, LMU München. Seit 2001 Professor für Klinische Biochemie, LMU München, seit 2012 am Institut für Laboratoriumsmedizin, Klinikum der LMU München.
Rights and permissions
About this article
Cite this article
Schaschke, N., Sommerhoff, C.P. β-Tryptase-Inhibitoren als Wirkstoffe gegen allergisches Asthma. Biospektrum 20, 517–519 (2014). https://doi.org/10.1007/s12268-014-0475-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12268-014-0475-5